Pharmacogenomics Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacogenomics, including details on pharmacology, designer drugs, customized medicines.

Racializing drug design: implications of pharmacogenomics for health disparities.

Lee SS

Stanford Center for Biomedical Ethics, Stanford University, Palo Alto, CA 94304, USA. sandra.lee@stanford.edu

Current practices of using "race" in pharmacogenomics research demands consideration of the ethical and social implications for understandings of group difference and for efforts to eliminate health disparities. This discussion focuses on an "infrastructure of racialization" created by current trajectories of research on genetic differences among racially identified groups, the use of race as a proxy for risk in clinical practice, and increasing interest in new market niches by the pharmaceutical industry. The confluence of these factors has resulted in the conflation of genes, disease, and race. I argue that public investment in pharmacogenomics requires careful consideration of current inequities in health status and social and ethical concerns over reifying race and issues of distributive justice.

Published 23 November 2005 in Am J Public Health, 95(12): 2133-8.
Full-text of this article is available online (may require subscription).

© 2005-2008 Pharmacogenomics Research Today. All Rights Reserved.